These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 10718489)

  • 21. Randomized trial of black cohosh for the treatment of hot flashes among women with a history of breast cancer.
    Jacobson JS; Troxel AB; Evans J; Klaus L; Vahdat L; Kinne D; Lo KM; Moore A; Rosenman PJ; Kaufman EL; Neugut AI; Grann VR
    J Clin Oncol; 2001 May; 19(10):2739-45. PubMed ID: 11352967
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adjuvant hormonal therapy for premenopausal women with breast cancer.
    Emens LA; Davidson NE
    Clin Cancer Res; 2003 Jan; 9(1 Pt 2):486S-94S. PubMed ID: 12538505
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ovarian ablation versus goserelin with or without tamoxifen in pre-perimenopausal patients with advanced breast cancer: results of a multicentric Italian study.
    Boccardo F; Rubagotti A; Perrotta A; Amoroso D; Balestrero M; De Matteis A; Zola P; Sismondi P; Francini G; Petrioli R
    Ann Oncol; 1994 Apr; 5(4):337-42. PubMed ID: 8075030
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Red clover and lifestyle changes to contrast menopausal symptoms in premenopausal patients with hormone-sensitive breast cancer receiving tamoxifen.
    Ferraris C; Ballestra B; Listorti C; Cappelletti V; Reduzzi C; Scaperrotta GP; Pulice I; Ferrari EGA; Folli S; Mariani L; Martelli G
    Breast Cancer Res Treat; 2020 Feb; 180(1):157-165. PubMed ID: 31975316
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Using traditional acupuncture for breast cancer-related hot flashes and night sweats.
    de Valois BA; Young TE; Robinson N; McCourt C; Maher EJ
    J Altern Complement Med; 2010 Oct; 16(10):1047-57. PubMed ID: 20954961
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial.
    Cuzick J; Sestak I; Cella D; Fallowfield L;
    Lancet Oncol; 2008 Dec; 9(12):1143-8. PubMed ID: 18976959
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hormonal approaches to breast cancer treatment and prevention: an overview.
    Vogel CL
    Semin Oncol; 1996 Aug; 23(4 Suppl 9):2-9. PubMed ID: 8824459
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cyclophosphamide, methotrexate, and fluorouracil versus tamoxifen plus ovarian suppression as adjuvant treatment of estrogen receptor-positive pre-/perimenopausal breast cancer patients: results of the Italian Breast Cancer Adjuvant Study Group 02 randomized trial. boccardo@hp380.ist.unige.it.
    Boccardo F; Rubagotti A; Amoroso D; Mesiti M; Romeo D; Sismondi P; Giai M; Genta F; Pacini P; Distante V; Bolognesi A; Aldrighetti D; Farris A
    J Clin Oncol; 2000 Jul; 18(14):2718-27. PubMed ID: 10894871
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A randomized crossover trial of tamoxifen versus ovarian ablation for metastatic breast cancer in premenopausal women: a report of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial MA.1.
    Sawka CA; Pritchard KI; Shelley W; DeBoer G; Paterson AH; Meakin JW; Sutherland DJ
    Breast Cancer Res Treat; 1997 Jul; 44(3):211-5. PubMed ID: 9266100
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial.
    Gnant M; Mlineritsch B; Stoeger H; Luschin-Ebengreuth G; Heck D; Menzel C; Jakesz R; Seifert M; Hubalek M; Pristauz G; Bauernhofer T; Eidtmann H; Eiermann W; Steger G; Kwasny W; Dubsky P; Hochreiner G; Forsthuber EP; Fesl C; Greil R;
    Lancet Oncol; 2011 Jul; 12(7):631-41. PubMed ID: 21641868
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The addition of hormone therapy to tamoxifen does not prevent hot flashes in women at high risk for developing breast cancer.
    Osborne CR; Duncan A; Sedlacek S; Paul D; Holmes F; Vukelja S; Kasper M; Wilks S; Schneider A; McGee R; Meyer WG; O'Shaughnessy JA
    Breast Cancer Res Treat; 2009 Aug; 116(3):521-7. PubMed ID: 19139988
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Is it time to develop an optimal endocrine therapy for premenopausal patients with axillary node positive and negative breast cancer?
    Bilimoria MM; Jordan VC
    Semin Surg Oncol; 1996; 12(5):339-45. PubMed ID: 8873322
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fulvestrant plus goserelin versus anastrozole plus goserelin versus goserelin alone for hormone receptor-positive, HER2-negative tamoxifen-pretreated premenopausal women with recurrent or metastatic breast cancer (KCSG BR10-04): a multicentre, open-label, three-arm, randomised phase II trial (FLAG study).
    Kim JY; Im SA; Jung KH; Ro J; Sohn J; Kim JH; Park YH; Kim TY; Kim SB; Lee KS; Kim GM; Kim SH; Kim S; Ahn JS; Lee KH; Ahn JH; Park IH; Im YH;
    Eur J Cancer; 2018 Nov; 103():127-136. PubMed ID: 30223226
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ovarian ablation as a treatment for breast cancer.
    Sainsbury R
    Surg Oncol; 2003 Dec; 12(4):241-50. PubMed ID: 14998564
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Postchemotherapy adjuvant tamoxifen therapy beyond five years in patients with lymph node-positive breast cancer. Eastern Cooperative Oncology Group.
    Tormey DC; Gray R; Falkson HC
    J Natl Cancer Inst; 1996 Dec; 88(24):1828-33. PubMed ID: 8961972
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An individual patient-based meta-analysis of tamoxifen versus ovarian ablation as first line endocrine therapy for premenopausal women with metastatic breast cancer.
    Crump M; Sawka CA; DeBoer G; Buchanan RB; Ingle JN; Forbes J; Meakin JW; Shelley W; Pritchard KI
    Breast Cancer Res Treat; 1997 Jul; 44(3):201-10. PubMed ID: 9266099
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Influence of hormone replacement therapy on tamoxifen-induced vasomotor symptoms.
    Sestak I; Kealy R; Edwards R; Forbes J; Cuzick J
    J Clin Oncol; 2006 Aug; 24(24):3991-6. PubMed ID: 16921052
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VII.
    Crivellari D; Bonetti M; Castiglione-Gertsch M; Gelber RD; Rudenstam CM; Thürlimann B; Price KN; Coates AS; Hürny C; Bernhard J; Lindtner J; Collins J; Senn HJ; Cavalli F; Forbes J; Gudgeon A; Simoncini E; Cortes-Funes H; Veronesi A; Fey M; Goldhirsch A
    J Clin Oncol; 2000 Apr; 18(7):1412-22. PubMed ID: 10735888
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oral clonidine in postmenopausal patients with breast cancer experiencing tamoxifen-induced hot flashes: a University of Rochester Cancer Center Community Clinical Oncology Program study.
    Pandya KJ; Raubertas RF; Flynn PJ; Hynes HE; Rosenbluth RJ; Kirshner JJ; Pierce HI; Dragalin V; Morrow GR
    Ann Intern Med; 2000 May; 132(10):788-93. PubMed ID: 10819701
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adjuvant endocrine therapy for premenopausal women: Type and duration.
    Francis PA
    Breast; 2017 Aug; 34 Suppl 1():S108-S111. PubMed ID: 28669713
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.